Letter Re: Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2.
作者信息
Zhu W, Wei Z, Xie R
机构信息
The Second Clinical Medical College, Lanzhou University, Gansu, China.
Guangzhou Institute of Cancer Research, The Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, China.
出版信息
ESMO Open. 2025 Jun;10(6):105313. doi: 10.1016/j.esmoop.2025.105313. Epub 2025 Jun 3.
Abstract
摘要
相似文献
1
Letter Re: Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2.关于fruquintinib联合最佳支持治疗的转移性结直肠癌患者的质量调整生存：FRESCO-2研究结果的信
ESMO Open. 2025 Jun;10(6):105313. doi: 10.1016/j.esmoop.2025.105313. Epub 2025 Jun 3.
2
Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2.呋喹替尼联合最佳支持治疗的转移性结直肠癌患者的质量调整生存期：FRESCO-2研究结果
ESMO Open. 2025 Mar;10(3):104297. doi: 10.1016/j.esmoop.2025.104297. Epub 2025 Feb 21.
3
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2.呋喹替尼对比安慰剂治疗难治性转移性结直肠癌患者：FRESCO-2安全性分析
Oncologist. 2025 Mar 10;30(3). doi: 10.1093/oncolo/oyae360.
4
FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer.FRESCO-2：一项全球性 III 期研究，旨在评估 fruquintinib 治疗转移性结直肠癌的疗效和安全性。
Future Oncol. 2021 Aug;17(24):3151-3162. doi: 10.2217/fon-2021-0202. Epub 2021 May 17.
5
Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in the FRESCO trial.在 FRESCO 试验中接受呋喹替尼治疗的转移性结直肠癌患者的质量调整生存。
Future Oncol. 2021 May;17(15):1923-1931. doi: 10.2217/fon-2020-1215. Epub 2021 Feb 10.
6
Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial.在中国既往治疗转移性结直肠癌患者中，呋喹替尼的安全性概况和特别关注的不良事件：III 期 FRESCO 试验分析。
Adv Ther. 2020 Nov;37(11):4585-4598. doi: 10.1007/s12325-020-01477-w. Epub 2020 Sep 8.
7
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.呋喹替尼对比安慰剂用于治疗难治性转移性结直肠癌患者（FRESCO-2）：一项国际、多中心、随机、双盲、III 期研究。
Lancet. 2023 Jul 1;402(10395):41-53. doi: 10.1016/S0140-6736(23)00772-9. Epub 2023 Jun 15.
8
Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer.FRESCO试验中按肝转移情况进行的亚组分析：比较呋喹替尼与安慰剂加最佳支持治疗用于中国转移性结直肠癌患者
Onco Targets Ther. 2021 Aug 11;14:4439-4450. doi: 10.2147/OTT.S307273. eCollection 2021.
9
Population Pharmacokinetics of Fruquintinib, a Selective Oral Inhibitor of VEGFR -1, -2, and -3, in Patients with Refractory Metastatic Colorectal Cancer.呋喹替尼（一种选择性口服VEGFR-1、-2和-3抑制剂）在难治性转移性结直肠癌患者中的群体药代动力学
J Clin Pharmacol. 2025 Jul;65(7):873-884. doi: 10.1002/jcph.70001. Epub 2025 Feb 19.
10
Comparing fruquintinib with placebo for treating patients with previously treated metastatic colorectal cancer: a plain language summary of the FRESCO-2 study.呋喹替尼与安慰剂治疗既往接受过治疗的转移性结直肠癌患者的比较：FRESCO-2研究的通俗易懂总结
Future Oncol. 2025 Feb;21(3):281-292. doi: 10.1080/14796694.2024.2425568. Epub 2024 Nov 29.
本文引用的文献
1
Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2.呋喹替尼联合最佳支持治疗的转移性结直肠癌患者的质量调整生存期：FRESCO-2研究结果
ESMO Open. 2025 Mar;10(3):104297. doi: 10.1016/j.esmoop.2025.104297. Epub 2025 Feb 21.
2
Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in the FRESCO trial.在 FRESCO 试验中接受呋喹替尼治疗的转移性结直肠癌患者的质量调整生存。
Future Oncol. 2021 May;17(15):1923-1931. doi: 10.2217/fon-2020-1215. Epub 2021 Feb 10.
3
The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy.一线姑息化疗期间转移性结直肠癌患者累积毒性对生活质量的预测价值。
Cancer Manag Res. 2018 Aug 29;10:3015-3021. doi: 10.2147/CMAR.S166468. eCollection 2018.
4
QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer.转移性结直肠癌中曲氟尿苷/替匹嘧啶的RECOURSE试验的质量调整生命年-无疾病进展生存期分析
ESMO Open. 2017 Nov 23;2(5):e000284. doi: 10.1136/esmoopen-2017-000284. eCollection 2017.
Zotero 插件